Quest Pharma to Develop Oncology Products
Posted on: Tuesday, 18 December 2007, 12:00 CST
Quest PharmaTech has signed a $3 million agreement with a multinational technology development company to develop oncology products based on its SonoLight Technology.
Under the terms of the agreement, Quest Pharma has already received $1,000,000; and the balance of $2,000,000 will be paid within the next twelve months. In return for this non-equity funding, the investor will receive 35% of all future net revenue from the commercialization of Quest's oncology products. This agreement does not preclude Quest from out-licensing the oncology applications of SonoLight technology to a third party.
The company's lead oncology product from the SonoLight platform, SL052, is anticipated to enter a Phase I clinical trial for photodynamic therapy treatment of prostate cancer during the second half of 2008. The company is also evaluating the same technology for the treatment of lung cancer and peritoneal carcinomatosis.
Madi Madiyalakan, CEO of Quest, said: "We are optimistic about the potential of both our oncology products and our dermatology program."
Source: Datamonitor
Related Articles
- Calypso Medical and Siemens Healthcare Sign Product Collaboration Agreement
- ExxonMobil Signs Long-Term Production Sharing Agreement With Petronas
- More Than 4,000 Products Wi-Fi Certified(TM) By the Wi-Fi Alliance(R)
- Eisai Announces Completion of Acquisition of Four Oncology-Related Products From Ligand
- BG Group Enters Oman With Exploration and Production Sharing Agreement
- Zaldiva, Inc. Now Offering Over 10,000 Products
- Delta College to Pay Enron: $142,000 Part of Agreement Over 2001's Bills
- Iraqi Minister Denies Product Sharing Agreement, Warns of Oil Smuggling Mafia
- Jordanian Government Cabinet Endorses Sonoran Energy's Production Sharing Agreement
- DataMEG Corp. Subsidiary NECI Signs Exclusive Pacific Rim Product-Distribution Agreement
 |
 |
User Comments (0)
RSS Feeds